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Introduction
Type 2 diabetes mellitus, a global epidemic, affects approximately 21 million people in the United States (1) . According to the 2005-2006 National Health and Nutrition Examination Survey (NHANES), the standardized total diabetes prevalence was 17.4% among both men and women, which reflects an absolute increase from the 1988-1994 NHANES of 3.7% among women compared with 2.1% among men (2) . During this period, the number of women with undiagnosed type 2 diabetes increased, whereas the number of men with undiagnosed diabetes decreased. Given the damaging effect of prolonged undetected hyperglycemia, prevention and early diagnosis of type 2 diabetes is cost-saving and of public health importance (3).
Diagnosis of both gestational diabetes mellitus (GDM) and milder abnormal glucose tolerance in pregnancy helps health care professionals identify women who are at high risk for type 2 diabetes (4-7). GDM confers a 7-fold risk for 
Methods

Data sources
To review postpartum screening rates and studies designed to prevent progression to type 2 diabetes among women with a history of GDM, we searched published journal articles in English from January 1, 2008, through December 31, 2010. We focused on the most recent literature to augment and update other recent reviews. We searched PubMed by using the search terms 1) "gestational diabetes" and "postpartum" or 2) or "gestational diabetes" and "follow-up." We also included additional articles that we identified by reviewing reference lists of studies and review articles.
Study selection and data extraction
Our initial search returned 265 articles. Two authors (A.T. and E.O.) independently reviewed titles and abstracts and obtained all potential articles for additional review; they also conducted all data abstraction and reached consensus through discussion about any disagreement. Articles that were deemed irrelevant and excluded from the review were related to screening for GDM during pregnancy only, screening for metabolic syndrome or cardiovascular disease, or maternal or infant outcomes associated with GDM, type 1 diabetes, obesity during pregnancy, fertility and obstetric complications, interventions during pregnancy to improve GDM or improve pregnancy outcomes for mother or infant, or articles related to other diseases during pregnancy such as preeclampsia or polycystic ovary syndrome. Relevant articles reported on the following topics: 1) recommendations for types of screening tests, 2) rates and results of diabetes screening among women with prior GDM diagnosis at any time period postpartum, 3) results and comparisons of different types of screening tests, 4) predictors of and barriers to screening, and 5) interventions to improve rates of postpartum diabetes screening. We identified 11 published studies that evaluated rates and results of postpartum screening for diabetes among women with GDM (1-3) and 21 studies that discussed predictors of and barriers to screening or interventions to improve rates of postpartum diabetes screening (4, 5) . We discuss findings for the first postpartum year and the later postpartum period separately.
Results
Postpartum screening for type 2 diabetes among women with GDM
Both the American College of Obstetricians and Gynecologists (10) and the American Diabetes Association (3, 14) recommend that women whose pregnancy was complicated by GDM be screened for persistent glucose abnormality at 6 to 12 weeks postpartum with either a fasting plasma glucose (FPG) test alone or with a fasting 75-g, 2-hour oral glucose tolerance test (OGTT). The OGTT is more sensitive, with reported sensitivities of 100% compared with 67% for FPG. The FPG test may be more acceptable to women because it requires less time, which could help overcome attrition in attendance for repeated follow-up testing in addition to being more easily tolerated (13, 15) . Criteria for diagnosing diabetes postpartum via a 75-g OGTT are similar to those for nonpregnant adult women (3), and thus results can identify overt diabetes mellitus, impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or normal glycemia; however, the FPG test can identify IFG but not IGT. Both the American College of Obstetricians and Gynecologists and the American Diabetes Association recommend that women with a history of GDM with a normal postpartum screening be rescreened every 3 years, and women with IFG or IGT or both (prediabetes) should be rescreened annually. Recent consensus guidelines recommend followup testing with an OGTT at 1 year postpartum, FPG test yearly, and consideration of an OGTT at 3 years (16).
Rates and results of postpartum screening for type 2 diabetes mellitus
We identified 11 studies published from 2008 through 2010 (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) that evaluated rates of postpartum screening for diabetes among women with GDM; of those, 8 were based on review of medical records and 3 were based on mailed questionnaires or interviews (Table) . Together, these studies included 32,240 women with pregnancies complicated by GDM from 1999 through 2008. Postpartum diabetes screening rates varied but were generally poor: 34% to 73% (median, 48%) of women overall were screened.
Three of these studies included large, diverse populations of women receiving care at health maintenance organizations (HMOs) (24) .
Although the recommended timing of screening is 6 to 12 weeks postpartum, all but 1 of the studies included longer follow-up (18) . However, screening rates were not markedly improved when the time window was broader. For example in 2006, screening rates were 50.3% in a study within 3 months of postpartum followup (20), 48.2% to 51.0% in 2 studies within 6 months of postpartum follow-up (19, 22) , and 55.9% in a study within 12 months of postpartum follow-up (18) . Among women seen at Kaiser Southern California who were screened within 6 months, 41% were screened from 7 days through 6 weeks postpartum, 46% from 6 through 12 weeks postpartum, and 12% from 12 weeks through 6 months postpartum (19) .
The type of screening tests included and results varied across the studies. Ogonowski and Miazgowski and Swan et al included only OGTT (23, 25) . The other 9 studies included either FPG or OGTT (17) (18) (19) (20) (21) (22) 24, 26, 27) although, of these, 2 did not report percentages of women screened with each test (17, 21) . In 4 studies, 79% to 100% of women were screened with FPG (18) (19) (20) 27) , whereas in the remaining 3 studies, most women (56%-95%) were screened with OGTT (22, 24, 26) (Table) . A number of women screened postpartum were found to have type 2 diabetes (1.2%-4.5%) or prediabetes (12.2%-36%) (Table) . In Turkey, Kerimoglu et al reported that 50% (5 of 10) of the patients who received an OGTT and 7.4% (2 of 27) of the patients who received FPG were diagnosed with type 2 diabetes (27) . Other studies have found that up to one-third of women with GDM will have abnormal postpartum screening (diabetes, IFG, or IGT) (28, 29) . According to Kwong et al, using only FPG in postpartum screening would cause up to 75% of women with IGT or type 2 diabetes to be missed (22) . Similarly, Hunt et al found that of the women with postpartum OGTT with IGT, approximately one-third had outside range values on the 2-hour value alone (26) . These findings are consistent with a substantial literature that a single FPG has a sensitivity of 16% to 89% when compared with an OGTT (13, 15, 30) .
Three studies of postpartum screening rates used different methods and did not include test results. Almario et al identified women with GDM by using laboratory data from a university teaching hospital and found that only onethird of medical records included plans to perform postpartum screening (21). Morrison et al mailed questionnaires to Australian postpartum women with a history of GDM and found a higher rate of self-reported screening at any time (73.2%) compared with the 38%-45% elsewhere at the time of the study, although many fewer women (27.3%) received an OGTT within 6 to 8 weeks postpartum as per Australian recommendations (24) . Another survey of 77 Australian women with a GDM pregnancy found that 61% self-reported postpartum diabetes screening (25) .
Factors associated with likelihood of postpartum diabetes screening
Rates of diabetes screening among postpartum women with a history of GDM differed by race and ethnicity, although findings varied (Table) . et al found Hispanic women in another population were more likely to be screened (51% vs 48% of white women and 27% of African American women) (19) . Asian women were most likely to be screened compared with women of other racial and ethnic backgrounds (odds ratio, 1.4; 95% confidence interval, 1.2-1.5) (18, 19) . Other patient characteristics associated with higher rates of postpartum screening included older age, nulliparity, and higher income or education. Women who received prenatal care, were treated with insulin during pregnancy, or completed a 6-week postpartum visit were also more likely to receive a postpartum diabetes screening (Table) .
Of the 21 additional studies identified, 3 discussed barriers to postpartum screening (31) (32) (33) . Barriers to postpartum screening included provider, patient, and systemlevel issues. In surveys of providers in Massachusetts, North Carolina, and Canada, providers commonly identified lack of patient attendance at a postpartum visit as the primary reason for not completing postpartum screening (31, 32) . However, in a chart review of data from 197 Massachusetts women with pregnancies complicated by GDM from 2000 through 2001, Smirnakis et al found that 94% of the women completed postpartum Papanicolaou screening, whereas 67% received any postpartum glucose testing and only 37% had an FPG or OGTT (34) . Other barriers to postpartum screening identified by clinicians included 1) clinicans' perception that screening guidelines were "inconsistent," 2) patient cost or inconvenience (31), 3) lack of documentation of GDM on problem lists, and 4) poor communication between obstetricians and primary care providers (33) . Patients identified time pressure as a primary barrier (32) .
Postpartum reminders may help to improve diabetes screening rates. In a randomized trial of 223 women, mailed reminders resulted in improved screening rates within 12 months postpartum when sent to physicians only (52%), patients only (55%), or both (61%), compared with no reminders (14%) (35) . However, only 48% of women seen at a Canadian diabetes referral clinic completed postpartum glycemic screening, even though women were given laboratory requisitions before delivery and received a telephone reminder if testing was not completed by 6 months postpartum (22 
Diabetes screening after the early postpartum period
Risks for abnormal glycemia persist even after the early postpartum period. In a study by Retnakaran et al, among 70 women with GDM but normal OGTT at 3 months postpartum, 17% had prediabetes (IFG, IGT, or both) when reevaluated with OGTT at 12 months postpartum, compared with 3% of 73 women with normal glucose tolerance both during pregnancy and at 3 months postpartum (4). Even women with lesser degrees of abnormal glucose during pregnancy were at elevated risk for abnormal 12-month OGTT despite a normal 3-month OGTT (39) . Risk factors for abnormal 12-month screening included higher 3-month postpartum glucose, BMI, low density lipoprotein cholesterol, triglycerides, and leptin, and lower high density lipoprotein cholesterol and adiponectin (4).
Risks for prediabetes, type 2 diabetes, and metabolic syndrome continue to increase over time, since pregnancy. Recent studies found that 16% to 30% of women with GDM develop type 2 diabetes by 5 to 10 years postpartum (42) (43) (44) , and more cases accumulate even later. In a 2009 meta-analysis of 20 studies that included 675,455 women and 10,859 type 2 diabetes events, women with a GDM pregnancy had a nearly 7.5-fold increased risk of developing diabetes (8) . Within 5 years of a pregnancy complicated by GDM, women had a relative risk of 4.7, which increased to 9.3 in those who were examined more than 5 years postpartum. In a 2010 population-based cohort study of more than 6,000 women from northern Finland followed since their pregnancies in 1986, the cumulative incidence of diabetes continued to increase even at 20 years postpar-
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tum. Rates were particularly high among women with a history of GDM who were overweight (26%), compared with controls who had no risk factors for GDM (0.7%) (45) . Risk factors for late progression to type 2 diabetes are similar to risk factors for early progression and include low insulin sensitivity, insulin resistance and progressive insulin secretory defect, and gain in weight and body fat.
Although we identified several recent screening studies completed within the first postpartum year, we found no recent studies that evaluated rates of diabetes screening in clinical settings after this time period. We found only 1 published intervention to promote longer-term follow-up of women with a history of GDM; in South Australia beginning in 2002, women with GDM were invited to provide contact information to a GDM registry, which then sent women annual mailed reminders for glycemic screening and requests for diabetes screening updates beginning at 15 months postpartum (46) . Findings suggest that these reminders helped promote screening. While 56% of women reported glycemic screening in the first postpartum year (before the intervention began), 75% reported having been screened during the second postpartum year. However, fewer than half of eligible women responded to the update requests, and thus reporting bias was likely.
Discussion
Because the prevalence of type 2 diabetes is increasing among all groups in the United States and undiagnosed cases are particularly high among women, prevention and early diagnosis of type 2 diabetes have become public health priorities. A diagnosis of GDM identifies women who are at high risk for developing type 2 diabetes. We found that even recent studies published from 2008 through 2010 documented poor rates of postpartum screening for diabetes among women with pregnancies complicated by GDM.
Most of the studies we reviewed included follow-up periods longer than the recommended 6 to 12 weeks postpartum. Nevertheless, screening rates were low. This finding coincides with results from other studies, which suggest that some barriers to screening (eg, lack of patient attendance, inconsistency of screening guidelines, patient cost or inconvenience [31] , and poor communication between obstetricians and primary care providers [33] ) may persist beyond the recommended screening timeframe. Since risks for abnormal glycemia persist even after the early postpartum period (4,39), ongoing screening is required for women with a history of GDM every 1 to 3 years depending on the results of the postpartum screen and the likelihood of a future pregnancy. Although we found no recent studies that evaluated clinical screening for diabetes after the first postpartum year, rates of screening over the long term are probably even lower than during the early postpartum period. Further studies will be needed to evaluate the prevalence, predictors, and outcomes of long-term screening.
According to Lawrence et al, Kwong et al, and Hunt and Conway, many women with IGT or type 2 diabetes were likely missed when women were screened by using only an FPG test (19, 22, 26) . This finding is consistent with earlier studies that found that the FPG test alone has poor sensitivity for diagnosis of prediabetes and type 2 diabetes compared with OGTT (30); however, its greater convenience may result in higher screening rates (47) . Nevertheless, in 2007, Kim et al simulated postpartum screening for diabetes with FPG, OGTT, and hemoglobin A1c annually, every 2 years, and every 3 years over a period of 12 years, and found that OGTTs resulted in lower costs per case detected than FPG or hemoglobin A1c testing (48) . More recently, the American Diabetes Association has allowed for the use of hemoglobin A1c as a screening test among the general population at risk for diabetes (3) . Whether this test will be recommended for early postpartum screening remains unclear, but further research in this area is needed as the convenience and low participant burden of the hemoglobin A1c has the potential to increase screening rates.
Our review confirms that type 2 diabetes is common among postpartum women with a history of GDM and that screening is acceptable to many women. According to previous studies, screening is appropriate only if an effective intervention exists and if early identification and treatment result in improved outcomes (49 few postpartum years represent a particularly high-risk period for development of prediabetes or type 2 diabetes.
Randomized controlled trials of postpartum lifestyle interventions have not targeted women with GDM in particular, yet a recent systematic review found that 6 of 8 lifestyle interventions were effective at promoting postpartum weight loss (57) . Recent studies (25, 33, 58) suggest that ample opportunity exists to improve weight and related lifestyle behaviors among postpartum women with a history of GDM. In addition to the traditional behavior change targets of diet and physical activity, observational studies suggest that breastfeeding, adequate sleep, and avoidance of television viewing may also help minimize postpartum weight retention and diabetes risk (59) (60) (61) (62) .
We identified no studies of postpartum screening for diabetes among women with GDM that also included information on prepregnancy or early pregnancy glycemic status. Whereas historically GDM has been defined as "any degree of glucose intolerance with onset or first recognition during pregnancy" (63), more recently it has been recognized that this definition includes a spectrum of glycemia entering pregnancy, including women with pregestational prediabetes or type 2 diabetes and also those with transient abnormal glucose levels that resolve after delivery. As more women become pregnant at older ages and with higher weights, a fraction of women diagnosed with GDM may actually have undiagnosed prediabetes or overt type 2 diabetes (64-66). Even women with abnormal glucose levels during pregnancy that do not meet criteria for GDM are at increased risk for postpartum prediabetes and type 2 diabetes (7, 36) . Recent consensus guidelines recommend first-trimester screening among women at high risk as well as thresholds that allow for diagnosis of overt diabetes at the time of early third trimester screening, which will identify women who merit especially close postpartum follow-up (67) . As of 2011, these guidelines are endorsed by the American Diabetes Association (14) . Future studies with information on women's glycemic status throughout the reproductive years will be invaluable in understanding the effect of abnormal glucose on outcomes during and after pregnancy.
There were several limitations to this systematic review. Because most of these studies were conducted within a large HMO system, where structural interventions for follow-up are often in place, or in diabetes referral clinic populations, postpartum screening rates are probably even lower among the general population. Also, 2 of the identified studies that reported higher screening rates were completed in Australia, a country with a different health care system from that of the United States. Newly recommended guidelines for GDM diagnosis will identify a much larger number of US women, perhaps 1 in 5 pregnant women, who will require treatment during pregnancy and screening postpartum (67) . Future research is needed to assess the success of structural interventions in increasing postpartum screening rates in settings other than large HMOs, and also other intervention strategies such as those delivered directly to women via Internet, cell phone, or other technologies. Proven, cost-effective, and readily generalizable strategies to promote both early and ongoing postpartum diabetes screening among women with a history of GDM are greatly needed.
In conclusion, as rates of type 2 diabetes continue to increase, especially among women, more prevention opportunities are needed. Among women who experience glucose abnormalities during pregnancy, screening during the postpartum period offers a window of opportunity for early identification of diabetes and prediabetes. Although rates of screening have increased during the past several decades, these rates are still not optimal and need to increase, given the type 2 diabetes epidemic faced by both developed and developing nations. Increasing rates of screening may be challenging; different players (health care providers and public health workers) need to be involved. Future work should focus on reducing barriers to screening for both providers and patients. Lifestyle interventions specific to women with history of GDM are needed, as are studies to determine the efficacy and safety of pharmacological interventions among women of childbearing age. 
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